Talphera (NASDAQ:TLPH) Stock Rating Upgraded by Maxim Group

Maxim Group upgraded shares of Talphera (NASDAQ:TLPH) to a strong-buy rating in a report issued on Friday,Zacks.com reports.

Separately, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Talphera in a research note on Friday, August 16th.

Talphera Stock Performance

Talphera stock opened at $0.89 on Friday. Talphera has a 52 week low of $0.43 and a 52 week high of $1.61. The firm has a market capitalization of $15.12 million, a price-to-earnings ratio of -1.39 and a beta of 0.31. The company has a 50 day moving average price of $0.91 and a 200 day moving average price of $0.94.

Talphera (NASDAQ:TLPH) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.22) by $0.07. Equities analysts forecast that Talphera will post -0.73 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in TLPH. Turtle Creek Wealth Advisors LLC acquired a new position in Talphera during the second quarter worth $64,000. Nantahala Capital Management LLC acquired a new stake in Talphera in the second quarter valued at $1,773,000. Finally, Rosalind Advisors Inc. acquired a new stake in Talphera in the third quarter valued at $650,000. Institutional investors and hedge funds own 37.67% of the company’s stock.

About Talphera

Talphera, Inc, a specialty pharmaceutical company, focuses on the development and commercialization of therapies for use in medically supervised settings. Its lead product candidate is Niyad, a lyophilized formulation of nafamostat, which is under an investigational device exemption as an anticoagulant for the extracorporeal circuit.